 |
 |
 |
 |
 |
 |
|
Member Profiles: Group Leader: Lab Heads: |
|
 |
|
 |
Laboratory Members
Dr Bryce J.W. van Denderen
Head, Gene Targeting & Regulation
Senior Research Officer
Protein Chemistry & Metabolism Unit
St Vincent's Institute
Telephone: +61 3 9288 2480
Facsimile: +61 3 9416 2676
Email: bvandenderen@svi.edu.au
Education:
|
Doctor of Philosophy (Melb), Bsc Hons (Melb) |
Awards:
| 1993-1995 | Melbourne University Postgraduate Scholarship (MUPS) |
| 1993 | Australian National Heart Foundation Travel Scholarship |
| 1994 | Immunology Group of Victoria student award |
| 1995/1996 | Transplantation Society of Australia and New Zealand young investigator award |
| 1995 | Transplantation Society of Australia and New Zealand international travel award |
| 1996 | International Transplantation Society Travel Award |
| 1997 | Janssen-Cilag Travelling Fellowship |
| 1997-1999 | INSERM 'Poste Vert' Post-doctoral Research Fellowship |
| 1999 | American Society of Transplant Physicians, 'Poster of Distinction' |
Research Interests:
The major interest of my research involves studying mechanisms of activation and the downstream actions of the cellular protein AMP-activated protein kinase, or AMPK. Its' pivotal role in energy metabolism makes it an attractive target to treat diseases such as obesity, diabetes and cardiovascular disease. More specifically my research involves generating and characterising genetically modified mice that contain deletions or alterations in the AMPK genes, as well as the genes of downstream targets. These genetic manipulations have been performed using knockout, conditional knockout, knockin and transgenic technologies. We currently have both b1 and b2 AMPK knockout mice that we are characterising, and are breeding whole body double and tissue-specific b1/b2 knockout mice. These animals will allow us to measure the importance of AMPK and its substrates in the whole animal under normal physiological and pathological conditions.
Additional research interests include identifying the mechanisms underlying the control of expression of the AMPK genes. This includes regulation of gene transcription through the use of alternative promoters, alternative splicing and factors within the 3-UTR which regulate transcript stability.
Representative publications from a total of 24:
- Iseli, T.J., Walter, M., van Denderen, B.J., Katsis, F., Witters, L.A., Kemp, B.E., Michell, B.J. and Stapleton, D. (2005) AMPK beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). J Biol Chem 280, 13395-400.
- Steinberg, G.R., Smith, A.C., Van Denderen, B.J., Chen, Z., Murthy, S., Campbell, D.J., Heigenhauser, G.J., Dyck, D.J. and Kemp, B.E. (2004) AMP-activated protein kinase is not down-regulated in human skeletal muscle of obese females. J Clin Endocrinol Metab, 89, 4575-4580.
- Peche, H., van Denderen, B., Roussel, J.C., Trinite, B., Soulillou, J.P. and Cuturi, M.C. (2004) Presentation of donor major histocompatibility complex class II antigens by dna vaccination prolongs heart allograft survival. Transplantation, 77, 733-740.
- Wiatrowski, H.A., Van Denderen, B.J., Berkey, C.D., Kemp, B.E., Stapleton, D. and Carlson, M. (2004) Mutations in the gal83 glycogen-binding domain activate the snf1/gal83 kinase pathway by a glycogen-independent mechanism. Mol Cell Biol, 24, 352-361.
- Adams, J., Chen, Z.P., Van Denderen, B.J., Morton, C.J., Parker, M.W., Witters, L.A., Stapleton, D. and Kemp, B.E. (2004) Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site. Protein Sci, 13, 155-165.
- Polekhina, G., Gupta, A., Michell, B.J., van Denderen, B., Murthy, S., Feil, S.C., Jennings, I.G., Campbell, D.J., Witters, L.A., Parker, M.W., Kemp, B.E. and Stapleton, D. (2003) AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol, 13, 867-871.
- van Denderen B.J.W., P￪che H, Gagne K, Cuturi M-C, Soulillou JPS, 2001. Identification of immunodominant donor MHC peptides following rejection and donor strain transfusion-induced tolerance of heart allografts in adult rats. Eur J Immunol. 31(5):1333-9.
- van Denderen B.J.W., Salvaris E, Romanella M,. Aminian A,. Katerelos M, Tange M., Pearse M.J., d'Apice A.J.F. 1997. Combination of decay-accelerating factor expression and a1,3-galactosyltransferase knock-out affords added protection from human complement-mediated injury. Transplantation 64: 882-888.
- van Denderen B.J.W., Pearse M.J., Katerelos M., Nottle M.B., Du Z-T., Aminian A., Adam W.R., Shenoy-Scaria A., Lublin D.M., Shinkel T.A., d'Apice A.J.F., 1996. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation. 61: 582-588.
- Tearle R.G., Tange M.J., Zannettino Z.L., Katerelos M., Shinkel T.A., van Denderen B.J.W., Lonie A.J., Lyons I., Nottle M.B., Cox T., Becker C., Peura A. M., Wigley P.L., Crawford R.J., Robins A.J., Pearse M.J., d'Apice A.J.F., 1996. The a-1,3-Galactosyltransferase knockout mouse: Implications for xenotransplantation. Transplantation 61: 13-19.
- Chen C-G., Fisicaro N., Shinkel T.A., Aitken V., Katerelos M., van Denderen B.J.W., Tange M.J., Crawford R.J., Robins A.J., Pearse M.J., d'Apice A.J.F., 1996. Reduction in Gal- a1,3-Gal epitope expression in transgenic mice expressing human H-transferase. Xenotransplantation 3: 69-75.
